Anti-CXCL12 Antibody Molecules and Their Uses
AssigneeCancer Research Technology Limited
InventorsFrances Rosemary Balkwill, John McCafferty, Gerard John Graham, Aneesh Karatt Vellatt, Peter Slavny
Life of this patent
Estimating the term…
Abstract
Anti-CXCL12 antibody molecules and their uses are disclosed, and in particular anti-CXCL12 antibody molecules that are capable of inhibiting a biological activity of CXCL12 in vitro and in vivo and their use for treating CXCL12-mediated disease.
Claims34
An isolated anti-CXCL12 antibody molecule which specifically binds to human CXCL12 and inhibits CXCL12-mediated biological activity, wherein the antibody molecule binds to an epitope of CXCL12 having the amino acid sequence as set out in SEQ ID NO:
- 24 that comprises amino acids (a) P10 and R12, and optionally one or more of E15, I28, P32, N45 and/or K54 or (b) P10 and Q48, and optionally one of more of K54 and N45.
An isolated anti-CXCL12 antibody molecule which specifically binds to human CXCL12 and inhibits CXCL12-mediated biological activity, wherein the antibody molecule comprises (a) a CDR-H1 having the amino acid sequence of SEQ ID NO:
- 12, or the amino acid sequence of SEQ ID NO:
- 12 with one, two, three or more amino acid substitutions, deletions or insertions, and (b) a CDR-H2 having the amino acid sequence of SEQ ID NO:
- 13, or the amino acid sequence of SEQ ID NO:
- 13 with one, two, three or more amino acid substitutions, deletions or insertions, and (c) a CDR-H3 having the amino acid sequence of SEQ ID NO:
- 14, or the amino acid sequence of SEQ ID NO:
- 14 with one, two, three or more amino acid substitutions, deletions or insertions.
An isolated anti-CXCL12 antibody molecule which specifically binds to human CXCL12 and inhibits CXCL12-mediated biological activity, wherein the antibody molecule comprises:
- (a) a CDR-H1 having the amino acid sequence of SEQ ID NO:
- 1, or the amino acid sequence of SEQ ID NO:
- 1 with one, two, three or more amino acid substitutions, deletions or insertions, (b) a CDR-H2 having the amino acid sequence of SEQ ID NO:
- 2, or the amino acid sequence of SEQ ID NO:
- 2 with one, two, three or more amino acid substitutions, deletions or insertions and (c) a CDR-H3 having the amino acid sequence of SEQ ID NO:
- 3, or the amino acid sequence of SEQ ID NO:
- 3 with one, two, three or more amino acid substitutions, deletions or insertions.
The anti-CXCL12 antibody molecule of any one of the preceding claims, wherein the anti-CXCL12 antibody binds CXCL12 and comprises:
- an antibody VH domain selected from the group consisting of the 114_3H1 VH domain (SEQ ID NO:
- 7) and a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO:
- 3 and optionally one or more VH CDRs with an amino acid sequence selected from SEQ ID NO:
- 1 and SEQ ID NO:
- 2;
- and/or
- an antibody VL domain selected from the group consisting of the 114_3H1 VL domain (SEQ ID NO:
- 9) and a VL domain comprising one or more VL CDRs with an amino acid sequence selected from SEQ ID NOs:
- 4, 5 and 6.
The anti-CXCL12 antibody molecule of any one of the preceding claims, wherein the anti-CXCL12 antibody binds CXCL12 and comprises:
- an antibody VH domain selected from the group consisting of the 113_1H12 VH domain (SEQ ID NO:
- 18) and a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO:
- 14 and optionally one or more VH CDRs with an amino acid sequence selected from SEQ ID NO:
- 12 and SEQ ID NO:
- 13;
- and/or
- an antibody VL domain selected from the group consisting of the 113_1H12 VL domain (SEQ ID NO:
- 20) and a VL domain comprising one or more VL CDRs with an amino acid sequence selected from SEQ ID NOs:
- 15, 16 and 17.
The anti-CXCL12 antibody molecule of any one of the preceding claims, wherein the antibody molecule is a complete antibody, a monoclonal antibody, a Fab fragment, a F(ab′)2 fragment, a scFv, a scFv-Fc, an intrabody, a nanobody, a diabody, a triabody, a bispecific antibody and a chimeric antibody.
The anti-CXCL12 antibody molecule of any one of the preceding claims wherein the antibody molecule is a human antibody or a humanised antibody.
Dependencies are inferred from the claim text.